Search company, investor...
Adrenomed company logo


Founded Year



Series E | Alive

Total Raised


Last Raised

$26.68M | 2 yrs ago

About Adrenomed

Adrenomed is a Gernan biopharmaceutical company focused on discovering and developing monoclonal antibody therapies that target the vasoactive adrenomedullin system in order to treat sepsis, septic shock and acute kidney injury.

Headquarters Location

Neuendorfstraße 15A

Hennigsdorf, 16761,


+49 (0) 3302 20 77 8 0

Missing: Adrenomed's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Adrenomed's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Adrenomed

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Adrenomed is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Adrenomed Patents

Adrenomed has filed 15 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Intensive care medicine
  • Proteins
patents chart

Application Date

Grant Date


Related Topics




Intensive care medicine, Clusters of differentiation, G protein coupled receptors, Syndromes, Proteins


Application Date


Grant Date



Related Topics

Intensive care medicine, Clusters of differentiation, G protein coupled receptors, Syndromes, Proteins



Latest Adrenomed News

Meet some of the biotechs attending Bio-Europe Spring 2023

Mar 10, 2023

Destiny Pharma Clinical-stage biotech Destiny Pharma based in the UK, develops novel approaches to the prevention of life-threatening infectious diseases . The Alternative Investment Market (AIM) traded firm’s diversified pipeline targets a broad range of indications. It has two Phase 3 clinical trial ready assets addressing areas of high unmet medical need with significant, billion-dollar, potential global commercial opportunity in addition to a range of earlier research programmes. Destiny’s flagship assets include XF-73 nasal gel , derived from its proprietary XF Platform, for the prevention of post-surgical Staphylococcus aureus infections, and the biotherapeutic product NTCD-M3 for the prevention of recurring C. difficile gut infections, the leading cause of hospital acquired infection in the US. In line with its strategy of finding partners to join up with on Phase 3 development and lead commercialization, the Company recently inked a $570 million co-development deal with the U.S.-based Sebela granting the GI specialist the North American rights to the treatment while leading and financing clinical development and commercialization activities in the region. Destiny CEO Neil Clark said that the company was “[..] very pleased to have reached this agreement,” noting that GI specialist company Sebela has the necessary clinical development and commercialisation expertise to take NTCD-M3 through to launch. A Phase 3 study is expected to start in 2024. With development plans for its Phase 3 studies for its second late-stage clinical asset, XF-73 Nasal, finalized, the company has also expanded its partnering activities targeting to secure a commercialization partner in 2023. “Our aim is to end 2023 having secured partners for both of our lead assets to complete their final Phase 3 clinical studies, registration and approval in key markets – especially the United States,” said Clark. Heidelberg Pharma At the forefront of developing innovative antibody drug conjugates (ADCs), Germany-based Heidelberg Pharma specializes in the development of the toxin amanitin for the treatment of cancer. In this unique approach, amanitin is linked to antibodies using the company’s proprietary ATAC technology and used to inhibit RNA polymerase II, a novel treatment concept in oncology . Heidelberg Pharma intends to overcome tumor resistances and kill even dormant tumor cells with these so-called ATACs. The biopharma’s lead candidate HDP-101 is in a clinical phase I/IIa study for the treatment of Multiple Myeloma patients. Other drug candidates in the mix include HDP-102, which targets non-Hodgkin’s lymphoma, and HDP-103, which is being developed to treat metastatic castration-resistant prostate cancer; both of these ATACs are in their preclinical trial stages. The newest addition to the preclinical pipeline, HDP-104, targets a molecule overexpressed by a range of gastrointestinal tumors. Last year, the company announced that it had struck a $1 billion deal with Chinese pharma company Huadong Medicine for the commercialization of its pipeline in large parts of Asia. The company has also partnered with Japan-based Chiome Bioscience and multinational pharma Takeda for the development of ATACs. Adrenomed Established in 2009, Adrenomed is a German biopharma that focuses on precision medicine, incorporating a biomarker-guided approach in the treatment of sepsis, a life-threatening reaction to an infection. The clinical-stage company’s lead drug candidate Adrecizumab addresses the loss of vascular integrity and endothelial barrier function, an important causal pathophysiology of septic shock. The non-blocking monoclonal antibody targets the vasoprotective peptide Adrenomedullin, an essential regulator of vascular integrity. A pre-specified biomarker analysis of the company’s clinical phase 2 trial in septic shock illustrated that treatment with Adrecizumab after ICU admission resulted in a rapid and sustained improvement of systemic organ function (SOFA score). Subsequently, the relative mortality was reduced by more than 30% after day 28. The positive effect on survival persisted over 90 days. Affecting around one in five deaths worldwide, sepsis accounts for around 11 million deaths annually, where the body’s immune response attacks its own tissues and organs. As a result, the company aspires to achieve global registration of Adrecizumab as it prepares for phase 3 clinical trials. Adrenomed has already received favorable feedback on the proposed study design, both from the European Medicines Agency and the U.S. Food and Drug Administration (FDA). Explore Related Topics:

Adrenomed Frequently Asked Questions (FAQ)

  • When was Adrenomed founded?

    Adrenomed was founded in 2009.

  • Where is Adrenomed's headquarters?

    Adrenomed's headquarters is located at Neuendorfstraße 15A, Hennigsdorf.

  • What is Adrenomed's latest funding round?

    Adrenomed's latest funding round is Series E.

  • How much did Adrenomed raise?

    Adrenomed raised a total of $53.9M.

  • Who are the investors of Adrenomed?

    Investors of Adrenomed include HBM Healthcare Investments and Wellington Partners.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.